Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06863402 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 15, 2026 to Nov 15, 2026
    • Eligibility criteria expanded, about 52 words
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Start date: Jun 15, 2026 to Aug 15, 2026
    • Eligibility criteria expanded, about 3 words
    v10
  3. Start date: Apr 15, 2026 to Jun 15, 2026
    • Primary completion pushed from Apr 1, 2029 to Jun 1, 2029
    • Study completion pushed from Apr 1, 2030 to Jun 1, 2030
    v9
  4. Start date: Feb 15, 2026 to Apr 15, 2026v8
  5. Start date: Nov 15, 2025 to Feb 15, 2026v7
Show 5 earlier versionsHide 5 earlier versions
  1. Start date: Oct 15, 2025 to Nov 15, 2025v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 136 words
    • Study description expanded, about 42 words
    • Site details revised
    v5
  3. Start date: Sep 1, 2025 to Oct 15, 2025v4
  4. Start date: Jul 1, 2025 to Sep 1, 2025v3
  5. Start date: Apr 1, 2025 to Jul 1, 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roswell Park Cancer Institute
113 trials monitored
See 13 trials at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
DLBCL
703 trials monitored
See 44 trials at risk
and 1 more disease
This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.
Trial Details
NCT Number NCT06863402
Lead Sponsor Roswell Park Cancer Institute
Conditions
(from sponsor)		 Richter Syndrome, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia
Related terms Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov